A Hemophagocytic Syndrome-Like Condition After Emergency Colectomy for Perforated Colon Cancer: Report of a Case

Surgery Today ◽  
2002 ◽  
Vol 32 (3) ◽  
pp. 278-281 ◽  
Author(s):  
Takayuki Yamada ◽  
Toshiro Ikeya ◽  
Tetsushi Ogawa ◽  
Minoru Nakano ◽  
Hidemi Ogura ◽  
...  
1992 ◽  
Vol 25 (8) ◽  
pp. 2232-2236
Author(s):  
Hiromi Nakayama ◽  
Koki Tanaka ◽  
Mitsunobu Uto ◽  
Akira Taira

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 482-482 ◽  
Author(s):  
Charlotte Emma Louise Klaver ◽  
Daniel D Wisselink ◽  
Cornelis J. A. Punt ◽  
Petur Snaebjornsson ◽  
Johannes Crezee ◽  
...  

482 Background: Patients with T4 or perforated colon cancer are at high risk (~25%) of peritoneal metastases (PM). Sensitivity of imaging modalities for PM is limited and the majority of patients is diagnosed in a palliative setting. This provides a rationale for adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC). In this study, the effectiveness of adjuvant HIPEC in reducing the risk of PM was determined. Methods: In this multicenter trial, patients with T4 (either cT4 or pT4, N0-2, M0) or perforated colon cancer, who underwent curative resection were randomized to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy or to adjuvant systemic chemotherapy alone (1:1). Adjuvant HIPEC with oxaliplatin was performed simultaneously (9%) or within five-eight weeks (91%) after the primary tumor resection. Patients without evidence of recurrent disease at 18 months based on CT imaging underwent diagnostic laparoscopy in both arms. The primary endpoint was PM free survival (PMFS) at 18 months using Kaplan Meier analysis. Results: Between April 2015 and January 2017, 204 patients were randomized: 102 in the control arm (0 drop-outs), 102 in the experimental arm (two drop-outs). Surgical exploration at the start of the HIPEC procedure at five-eight weeks postoperatively revealed metastases in 11 patients (PM in 9/11) in the experimental arm, and adjuvant HIPEC was not applied. Adjuvant systemic chemotherapy was administered in 89/100 eligible patients after median 6 weeks (IQR 5-7) in the control arm and in 84/89 after 10 weeks (IQR 9-12) in the experimental arm. PM rate after completion of 18 months follow-up was 22/102 and 18/100, respectively. In the ITT analysis no difference in 18 months PMFS was observed: 77% (control) versus 81% (experimental), HR 0.836 (0.489-1.428)). Also, no differences were observed in 18 months DFS (HR 1.016 (0.646-1.598)) and OS (HR 1.139 (0.532-2.439)). One patient developed encapsulating peritoneal sclerosis after HIPEC. Conclusions: Adjuvant HIPEC with oxaliplatin for patients with T4 or perforated colon cancer does not result in improved 18 months PMFS. Long-term results have to be awaited to assess the role of HIPEC in the adjuvant setting. Clinical trial information: NCT02231086.


2020 ◽  
Author(s):  
Chunyi Wu ◽  
Jy-Ming Chiang ◽  
Jeng-Fu You ◽  
Reiping Tang ◽  
Jinn-Shiun Chen ◽  
...  

Abstract Background: The neutrophil-to-lymphocyte ratio is a significant prognostic marker in resectable colorectal cancer; however, there are no equivalent findings for perforated colon cancer. Using our colorectal cancer database, we retrospectively analyzed the data from 1995 to 2015 to determine whether the preoperative neutrophil-to-lymphocyte ratio is associated with survival outcomes in patients with perforated colon cancer.Methods: One-to-one propensity score matching was applied to minimize the difference between the high (>5) and low (≤5) neutrophil-to-lymphocyte ratio groups. Clinicopathological factors, long-term overall survival, and disease-free survival were analyzed and compared between the two groups. The primary outcomes were overall survival and disease-free survival.Results: Before propensity score matching, the high neutrophil-to-lymphocyte ratio group had a significantly higher prevalence of leukocytosis (low vs. high neutrophil-to-lymphocyte ratio groups: 12 [12.9%] vs. 46 [59.7%], p<0.001), lower serum albumin levels (low vs. high neutrophil-to-lymphocyte ratio groups: 30 [32.3%] vs. 42 [54.5%], p=0.003), and a higher emergent operation rate (low vs. high neutrophil-to-lymphocyte ratio groups: 5 [5.4%] vs. 20 [26.0%], p<0.001). After one-to-one propensity score matching, the groups comprised 41 patients each; none of the parameters were significantly different between the two groups. The mean follow-up period was 76.3 months. The 5-year overall survival (p=0.637) and disease-free survival (p=0.827) rates were not significantly different between the high and low neutrophil-to-lymphocyte ratio groups.Conclusions: The neutrophil-to-lymphocyte ratio has limited predictive value for determining outcomes in patients with perforated colon cancer.


Author(s):  
Tairin Uchino ◽  
Shunichiro Komatsu ◽  
Tatsuki Matsumura ◽  
Yasuyuki Fukami ◽  
Takuya Saito ◽  
...  

2021 ◽  
Author(s):  
Joseph C Kong ◽  
Jordan Lee ◽  
Rathin Gosavi ◽  
Samuel Y Ngan ◽  
Matthew M Tillman ◽  
...  

2006 ◽  
Vol 30 (1) ◽  
pp. 95-96 ◽  
Author(s):  
Hsiao-Wen Ku ◽  
Kuang-Jui Chang ◽  
Tung-Yen Chen ◽  
Ching-Wen Hsu ◽  
Shyr-Chyr Chen

Aorta ◽  
2016 ◽  
Vol 04 (04) ◽  
pp. 131-133
Author(s):  
Taufiek Rajab ◽  
Daniel Rinewalt ◽  
Michael Belkin ◽  
Joel Goldberg ◽  
Haiyang Zhou

AbstractA 50-year-old male smoker presented with a perforated colon cancer and underwent an extended right colectomy. Feculent peritonitis was treated with empiric antibiotics. Postoperatively he developed severe back pain and rising leukocytosis. Serial computed tomography revealed a rapidly expanding infrarenal aortic aneurysm. He was urgently treated with extra-anatomic bypasses and aortic resection. No organisms grew from the resected aortic wall. He was discharged in stable condition, and the ileostomy was reversed 9 months later.


Sign in / Sign up

Export Citation Format

Share Document